A Phase 2 interventional study of Ianalumab and Eltrombopag in Primary Immune Thrombocytopenia (ITP), sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 20th largest by planned enrollment, is the only one that started in 2027, is one of 15 in phase 2, and was the 35th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 12–75
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis: 4 open now, 7 under way, 2 of them phase 3. Of 7 finished, 6 (86%) have results posted.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2027, is one of 7 in phase 2, and was the 15th registered.
Novartis’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2006.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 17 in Purpura, Thrombocytopenic, Idiopathic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to \<18 years of age) with primary ITP who have had an insufficient response to or relapsed after first-line treatment with corticosteroids.
The study will consist of 3 phases:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ianalumab in addition to eltrombopag.
Biological: Ianalumab · Drug: Eltrombopag
Liquid in a vial Concentrate for solution for infusion
Also known as: VAY736
Film-coated tablet and also Powder for oral suspension
Also known as: ETB115
Time to treatment failure (TTF)
TTF is defined as the time from start of treatment until any of a list of specific events is met.
Time frame: enrolled until end of study (up to 39 months from the last patient enrolled)
Stable response rate at 6 months (SR-6)
SR-6 is defined as the percentage of participants with a platelet count of at least 50 G/L at 75% of the measures taken between Study Day 121 and 183, in the absence of rescue or new Immune Thrombocytopenia (ITP) therapy.
Time frame: 6 months
Stable response rate at 12 months (SR-12)
SR-12 is defined as the percentage of participants with a platelet count of at least 50 G/L at 66% of the measures taken between Study Day 296 and 379, in the absence of rescue or new ITP therapy.
Time frame: 12 months
Complete Response (CR) rate
CR is defined as the percentage of participants with any platelet count of at least 100 G/L in the absence of rescue treatment or new ITP treatment.
Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)
Response Rate (RR)
RR is defined as the percentage of participants with any platelet count of at least 50 G/L in the absence of rescue treatment or new ITP treatment.
Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)
Time to response
Time to response is defined as the time from the start of treatment to the date of the first response.
Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)
Time to complete response
Time to complete response is defined as the time from the start of treatment to the date of complete response.
Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)
Duration of response
Duration of response is defined as the time from achievement of response (platelet count ≥ 50 G/L) to treatment failure.
Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)
Duration of complete response
Duration of complete response is defined as the time from achievement of response to loss of complete response.
Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)
Bleeding Events
Percentage of participants with bleeding events according to WHO Bleeding Scale
Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)
Rescue medication
Number and percentage of participants receiving rescue treatment
Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)
Rate of participants who successfully taper and discontinue eltrombopag - being treatment failure-free
Treatment failure-free (as defined for the primary efficacy endpoint) at the end of the planned Treatment period.
Time frame: End of Week 24
Ianalumab serum concentration (Cmax)
Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body.
Time frame: at pre-dose of each of the 4 dosing events and end-of-infusion and first and last dose
B cell levels: Change from baseline in the frequency (% within CD45+ cells) and absolute number of CD19+ B cells
Number and percentage of B-cell levels in the blood, and comparison with baseline levels of B-cells at specific timepoints.
Time frame: 12 months after the first treatment of the last enrolled participant, final dbl: until end of study (up to 39 months from the last patient enrolled)
B cell levels: Time to first occurrence of B cell recovery
Time to first occurrence of B cell recovery is defined as ≥80% of baseline or ≥50 cells/μL.
Time frame: 12 months after the first treatment of the last enrolled participant, final dbl: until end of study (up to 39 months from the last patient enrolled)
Immunoglobulins: Change from baseline in immunoglobulin levels
Change from baseline levels of serum immunoglobulins at specific timepoints.
Time frame: 12 months after the first treatment of the last enrolled participant, final dbl: until end of study (up to 39 months from the last patient enrolled)
Platelet counts: Change from baseline in platelet count
Change from baseline levels of platelets at specific timepoints.
Time frame: 12 months after the first treatment of the last enrolled participant, final dbl: until end of study (up to 39 months from the last patient enrolled)
Incidence and titer of anti-ianalumab antibodies in serum (anti-drug-antibody (ADA) assay)
Anti-drug antibodies (ADAs) are immune responses developed by a participant's body against biologic or gene therapies.
Time frame: over time (up to 39 months from the last patient enrolled)
No study locations are listed for this record.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Apr 2033, 74 months later.
Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 74 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ianalumab · Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →